Market Cap | 206.60M | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
Income | -2.11M | Forward P/E | - | EPS next Y | - | 50D Avg Chg | 5.00% |
Sales | 186k | PEG | - | EPS past 5Y | - | 200D Avg Chg | 147.00% |
Dividend | N/A | Price/Book | N/A | EPS next 5Y | - | 52W High Chg | -41.00% |
Recommedations | - | Quick Ratio | 0.16 | Shares Outstanding | 1.03B | 52W Low Chg | 99,950.00% |
Insider Own | - | ROA | - | Shares Float | 12.30M | Beta | - |
Inst Own | - | ROE | - | Shares Shorted/Prior | -/- | Price | 0.20 |
Gross Margin | -42.47% | Profit Margin | - | Avg. Volume | 39,822 | Target Price | - |
Oper. Margin | -1,133.87% | Earnings Date | - | Volume | 18,025 | Change | 0.00% |
Hong Chang Biotechnologies (HK) Limited was incorporated in 2023 and is based in Kowloon, Hong Kong. Hong Chang Biotechnologies (HK) Limited operates as a subsidiary of Zengqiang Investment Limited. As of September 4, 2023, Hong Chang Biotechnologies (HK) Limited operates as a subsidiary of Heyu Biological Technology Corporation.